GT Biopharma to Present at the Centurion One Capital 9th Annual Toronto Growth Conference

Core Insights - GT Biopharma, Inc. is a clinical stage immuno-oncology company focused on developing therapeutics based on its proprietary TriKE NK cell engager platform [1][3] - The company will participate in the Centurion One Capital 9th Annual Toronto Growth Conference on March 5, 2026, where one-on-one meetings with investors will be available [1][2] Company Overview - GT Biopharma is dedicated to the development and commercialization of immuno-oncology therapeutic products utilizing the TriKE platform, which enhances the cancer-killing abilities of natural killer cells in the immune system [3] - The company holds an exclusive worldwide license agreement with the University of Minnesota for the further development and commercialization of therapies using TriKE technology [3]